Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?

To: aknahow who wrote (16263)	9/14/2003 3:29:03 PM
From: Bluegreen	Read Replies (1) \| Respond to of 17367

Hey George, there may be SEVERAL mistakes in the article. I posted the link for the benefit of quotes from Jack Castello. Hopefully they got the quotes right. One other thing I might mention.......I have invested in Xoma for the future..........mainly the POSSIBLE future of Neuprex. I could care less about Raptiva except as a maybe a vehicle for possible Neuprex. I could see how companies like Genentech would go broke fast IF their products didn't cover the cost of bringing the product to market. One might go figure the numbers from there. IN OTHER WORDS......the human race should hope and pray that BIOLOGICS approved by the FDA are profitable or we just go back to the old poison chemical based drugs and forget about the genome project. OLD GENERICS ANYONE????? Hey they sure are cheap!!!!!